To include your compound in the COVID-19 Resource Center, submit it here.

Provenge: Phase II data; Phase III

DNDN published in the Journal of Clinical Oncology final results of its U.S.

Read the full 133 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE